Treatment options are limited for gout as compared to other forms of arthritis. The University of Michigan’s professor Puja Khanna and her co-workers blended two gout treatment options because of the slowness in introducing new drugs in the market.
It possibly takes between 10 and 20 years to get a new drug from the creation phase to its FDA-approved stage, said Puja Khanna. It is challenging to treat gout, and because gout medication options are limited, people like her are seeking innovative ideas. Khanna and her other team members’ piece of research, is heralded in the periodical for Arthritis and Rheumatology.
Anti-Drug Antibody Use
Gouty arthritis happens due to an excessive amount of uric acid situated in the flowing blood. Gout symptoms occur when the body develops inflammation as a response to the crystals of uric acid that form in our joints.
Krystexxa is among the biological drugs that medical professionals prescribe to individuals with serious, treatment-resistant gouty arthritis to lessen the levels of the acid in their bodies. The professionals deliver Krystexxa to the body in the form of shots. After that, it processes uric acid by metabolism into a safe substance that the human body expels.
Anyhow, when used alone, Krystexxa can trigger an immune reaction against itself. Then, the human body creates antibodies that can get rid of Krystexxa molecules, thus limiting the product’s efficacy.
According to George Washington University’s professor Herbert Baraf, that is a dilemma as it is often the last resort for those people with extremely severe gout. The team wished to see whether mycophenolate mofetil could not only make Krystexxa more able to keep uric acid’s level low but also limit antibody creation.
The second phase of Khanna and her team’s trial involved 32 people, who got either a placebo or mycophenolate mofetil before starting treatment through Krystexxa. Following 3 months, those study participants no longer got mycophenolate mofetil, but they kept receiving Krystexxa injections.
Of the people who got the two drugs together, 86% got the therapy-related target level of the acid in their blood serum in 12 weeks. Anyhow, that came down to 68% in 24 weeks.
Conversely, 40% of those participants who absorbed just Krystexxa got their therapeutic targets.
The results were similar in an earlier randomized phase II trial that looked at the efficacy of Krystexxa alone. Anyhow, Khanna feels that a higher rate of success is possible with combined treatment under different scenarios.